New biologic combo aims to spare bladders in cancer fight
NCT ID NCT07445308
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new biologic drug called SPGL008, given alone or with the standard therapy BCG, in 120 people with high-risk non-muscle-invasive bladder cancer who are not candidates for bladder removal. The main goals are to find a safe dose and see if the drug can control the cancer. The study is not yet recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SPGL008 (a biologic) alone or combined with BCG
- What this could lead to
- If successful, this could point toward a new treatment option for people with high-risk bladder cancer who cannot or choose not to have bladder removal surgery.
- What could go wrong
- This is an early-phase trial with only 120 participants, so it is too soon to know if SPGL008 works. Side effects are possible, and the combination with BCG may increase risks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NMIBC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple blood or urine test spot bladder cancer earlier?
- Can a Bladder-Instilled biologic keep recurrent bladder cancer at bay?
- Bladder cancer combo trial pulled before it began
- Engineered TB bacteria could offer new hope for bladder cancer patients
- Bladder cancer patients get new hope from virus therapy
- New hope for bladder cancer patients: experimental drug combo aims to beat chemo